Cardiovascular comorbidities were equally prevalent in full-dose and reduced-dose groups, suggesting well-controlled cardiovascular disease need not contraindicate standard dosing.

Outcomes remained poor overall, underscoring the need for clinical trials and novel therapies in this setting.

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

New research is helping to change the way investigators and clinicians think about and treat Richter transformation (RT) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Genetic predisposition and lifestyle factors both play crucial roles in diabetes management and onset. Cancer treatment can complicate diabetes management, requiring careful coordination between ...

Hope is crucial in the cancer journey, offering emotional resilience and strength through various forms like medical advancements and empathetic listening. AI-assisted technologies and new treatments ...